CHAPTER 2. HUMAN RESOURCE DEVELOPMENT
58
technology, this will certainly contribute to the future development of in vivo
immunosensors for real time measurement of chrono-biological changes of
whole blood analytes. In addition, there have also been rapid advances in solid
phase design, techniques in immobilization of chemicals such as self-assembly of
monolayers, and molecular visualization and micromachinery by atomic force
microscopy. These will certainly be applied to immunoassays in future to
increase assay sensitivity and specificity. All these new ‘black box’ immunoassay
methodologies, mostly protected by patent and copyright, have to be calibrated
against the gold standard set by RIA, which still remains the most robust and
cost effective immunoassay.
In the diagnostic industry, RIA is still used to set up the first workable
immunoassay methodology for new analytes before the then thoroughly
evaluated method is transformed into another commercial assay format. This
developmental role of RIA will be fully realized when the shift is made from the
present anatomical genomic information phase with massive amounts of genetic
information to the future proteomic action phase. In routine diagnostic areas,
RIA will continue to be used as the reference method to solve problems
generated by non-isotopic immunoassay as a result of analytical interference.
With the use of modular robotic systems and improved antibody design, RIA
can be automated to further reduce operational costs and is well suited to
nationwide targeted screening of congenital and other disorders.
In the final analysis, RIA will continue to play a major role in most
developing countries in supporting routine diagnostic services, especially for
infections, tumours, coronary heart disease, diabetes and degenerative diseases.
In more developed countries which are striving to achieve a comprehensive long
term development of diagnostic biotechnology, the method will be used more
frequently in the production processes of monoclonal antibodies.
2.8.2. Principle
Radioimmunoassay continues to maintain a favoured position among
microanalytical procedures not only because of its sensitivity, acceptable
precision, robustness (working best in non-optimal conditions) and wide appli
-
cability, but also because it is comparatively the least expensive of numerous
methods available for the detection and measurement of substances of clinical
diagnostic interest. The advantage of RIA methodology is that it is freely
available in the public domain — one of the major criteria for technology
transfer. It is amenable to bulk reagent based methodology, using at least some
locally produced reagents, in contrast to methods totally dependent on black
box type commercial kits. For this reason, RIA is seen to be the most suitable
option for developing countries, where financial constraints combined with an